Cancer Genetics to Present at "A Future Without Cancer Conference" on Friday, March 17
13 mars 2017 09h13 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced...
Cancer Genetics to Report Fourth Quarter & Year End 2016 Earnings and Business Update on March 23
10 mars 2017 11h41 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., March 10, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced...
Cancer Genetics India Partners with CSIR-Centre for Cellular and Molecular Biology to Organize the 2nd Annual Next Generation Sequencing Conference in India
23 févr. 2017 14h33 HE
|
Cancer Genetics, Inc.
Scientists at CSIR-CCMB conduct groundbreaking multi-disciplinary research in the area of modern biology and aim to promote collaborative research using advanced technologies that enable omics-based...
Cancer Genetics, Inc. to Receive $1.0 Million in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
22 févr. 2017 08h12 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) an emerging leader in enabling precision medicine for oncology through the use of molecular markers and...
Cancer Genetics, Inc. Hereditary Breast & Ovarian Cancer Panel Selected by Global Biopharma to Power 1,000+ Patient Clinical Study
16 févr. 2017 08h15 HE
|
Cancer Genetics, Inc.
Revenue from the study will begin immediately, and the Company expects it to continue through 2018The hereditary breast and ovarian panel, Focus::HERSite™, will also be offered for select...
Cancer Genetics, Inc. to Present at the 2nd Annual Disruptive Growth & Healthcare Conference
13 févr. 2017 07h30 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced...
Cancer Genetics, Inc. Launches Entry into Comprehensive Hereditary Cancer Testing for Breast & Ovarian Cancers, Addressing a $2.5 Billion Market
25 janv. 2017 12h48 HE
|
Cancer Genetics, Inc.
CGI believes that hereditary cancer testing will generate significant additional revenue from both clinical and biopharma customers during 2017 and beyond.Launch of hereditary panel, branded...
Precision Oncology Diagnostics Leader, Cancer Genetics, Inc. & Precision Therapeutics Company, Lantern Pharma, Inc. Announce Strategic Collaboration Focused on Drug Rescue & Repurposing Leveraging Genomics, Biomarkers & Artificial Intelligence Driven Development for Multiple Lead Oncology Compounds
17 janv. 2017 09h31 HE
|
Cancer Genetics, Inc.
The collaboration will leverage CGI’s biomarker discovery, clinical trial testing, and companion diagnostic development capabilities along with Lantern’s artificial intelligence and big-data driven...
Cancer Genetics, Inc. Announces Multiple Agreements & Collaborations to Develop Liquid Biopsy Programs with Leading Biopharma Companies
09 janv. 2017 09h27 HE
|
Cancer Genetics, Inc.
CGI has signed five agreements and contracts to develop focused, high-performance liquid biopsy tests for a broad range of solid tumorsThe liquid biopsy tests are focused on therapy monitoring &...
Cancer Genetics, Inc. Announces Consolidation and Cost Reduction in Administrative and Operational Support Functions
06 janv. 2017 17h34 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) an emerging leader in enabling precision medicine for oncology through the use of molecular markers and...